CompletedNCT03573297
A Cariprazine Study in the Prevention of Relapse in Bipolarity type I Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 107 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: June 15, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 901
- Sponsor
- AbbVie
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Bulgaria, Malaysia, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03573297
- Official title
Show the full official title
A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Cariprazine in a Dose-reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
Recruitment & locations
CompletedLittle Rock, United States · Rogers, United States · Anaheim, United States
89 more locations
- Bellflower, United States
- Cerritos, United States
- Costa Mesa, United States
- Culver City, United States
- Garden Grove, United States
- Glendale, United States
- La Habra, United States
- Lemon Grove, United States
- Long Beach, United States
- Orange, United States
- San Diego, United States
- San Marcos, United States
- Torrance, United States
- Colorado Springs, United States
- Hallandale, United States
- Hollywood, United States
- Jacksonville, United States
- Maitland, United States
- Miami Lakes, United States
- Tampa, United States
- Atlanta, United States
- Decatur, United States
- Dunwoody, United States
- Winfield, United States
- Shreveport, United States
- Gaithersburg, United States
- Saint Charles, United States
- Las Vegas, United States
- Berlin, United States
- Cedarhurst, United States
- Charlotte, United States
- Raleigh, United States
- Beavercreek, United States
- Columbus, United States
- Dayton, United States
- Oklahoma City, United States
- Austin, United States
- Richardson, United States
- The Woodlands, United States
- Burgas, Bulgaria
- Kardzhali, Bulgaria
- Kazanlak, Bulgaria
- Lovech, Bulgaria
- Pleven, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Targovishte, Bulgaria
- Ipoh, Malaysia
- Kuala Lumpur, Malaysia
- Lublin, Poland
- Gdansk, Poland
- Poznan, Poland
- Chełmno, Poland
- San Juan, Puerto Rico
- Kazan', Russia
- Moscow, Russia
- Nizhny Novgorod, Russia
- Orenburg, Russia
- Roschino, Russia
- Saint Petersburg, Russia
- Saratov, Russia
- Tomsk, Russia
- Tonnelniy, Russia
- Belgrade, Serbia
- Kragujevac, Serbia
- Novi Sad, Serbia
- Kovin, Serbia
- Novi Kneževac, Serbia
- Busan, South Korea
- Gwangju, South Korea
- Jeju City, South Korea
- Jeonju, South Korea
- Taipei City, Taiwan
- New Taipei City, Taiwan
- Taichung, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Chiang Mai, Thailand
- Muang, Thailand
- Smila, Ukraine
- Kryvbas Village, Ukraine
- Kharkiv, Ukraine
- Stepanivka Village, Ukraine
- Oleksandrivka Village, Ukraine
- Uzhhorod, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Vinnytsia, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is AbbVie.
Did this study involve medication?
Yes. The study involved medication, including Cariprazine and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me